[Recombinant Human Erythropoietin (r-HuEPO) therapy in a newborn with hereditary spherocytosis].
The newborn with hereditary spherocytosis can develop severe anemia, requiring red blood cell transfusions. Therapy with r-HuEPO has been proposed to avoid transfusions.


METHODS
Hereditary spherocytosis was diagnosed in a newborn who had severe and early jaundice. He was treated with r-HuEPO, and did not require red blood cells transfusion.


CONCLUSIONS
Recombinant erythropoïetin might be an interesting alternative to red blood cells transfusions during the neonatal period in newborns with hereditary spherocytosis.
Schiff
M
M
Service de néonatologie et de réanimation néonatale, hôpital Debrousse, 29, rue Soeur-Bouvier, 69322 cedex 05, Lyon, France. manuel.schiff@free.fr <manuel.schiff@free.fr>
Haÿs
S
S
Sann
L
L
Putet
G
G
D004334:Drug Administration Schedule; D017707:Erythrocyte Transfusion; D004921:Erythropoietin / Q000627:therapeutic use*; D006400:Hematocrit; D006454:Hemoglobins / Q000187:drug effects; D006801:Humans; D007231:Infant, Newborn; D007279:Injections, Subcutaneous; D007567:Jaundice, Neonatal / Q000209:etiology / Q000628:therapy; D008297:Male; D010789:Phototherapy; D011994:Recombinant Proteins; D017701:Reticulocyte Count; D013103:Spherocytosis, Hereditary / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin